Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability and PK of GSK3640254 in Healthy Participants
NCT03231943Phase 1Completed
- Sponsor
- ViiV Healthcare
- Start
- Sep 2017
- Primary completion
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of fipravirimat in human immunodeficiency virus type 1 infection (HIV-1) (3 arms), sponsored by ViiV Healthcare. Primary endpoints: Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs), Change From Baseline in Hematology Parameters and 4 more. Started Sep 2017; status: completed.
02
Drugs
fipravirimat
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT03231943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03231943.